Karen Paraska1, Catherine M Bender. 1. School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. kparaska@libcom.com
Abstract
PURPOSE/ OBJECTIVES: To describe the cognitive dysfunction experienced by two women after they received adjuvant chemotherapy for breast cancer and to discuss the potential role of changes in reproductive status and depression in the development of cognitive dysfunction. DATA SOURCES: Journal articles, research data, and clinical experience. DATA SYNTHESIS: Following chemotherapy, 17%-50% of women with breast cancer experience cognitive dysfunction that may include decrements in memory, attention, and psychomotor efficiency. One mechanism that may contribute to cognitive dysfunction involves changes in reproductive status resulting from chemotherapy. Additionally, the presence of depression may confound the experience of cognitive dysfunction. CONCLUSIONS: A comprehensive description of cognitive dysfunction and improved understanding of the interrelationships among cognitive dysfunction, reproductive hormone levels, and depression in women with breast cancer receiving adjuvant chemotherapy may hasten the development of interventions for the management of cognitive dysfunction. IMPLICATIONS FOR NURSING: Nurses should teach women with breast cancer and their families about the potential for cognitive dysfunction after chemotherapy so the problem can be recognized and interventions can be implemented to help women compensate for the dysfunction.
PURPOSE/ OBJECTIVES: To describe the cognitive dysfunction experienced by two women after they received adjuvant chemotherapy for breast cancer and to discuss the potential role of changes in reproductive status and depression in the development of cognitive dysfunction. DATA SOURCES: Journal articles, research data, and clinical experience. DATA SYNTHESIS: Following chemotherapy, 17%-50% of women with breast cancer experience cognitive dysfunction that may include decrements in memory, attention, and psychomotor efficiency. One mechanism that may contribute to cognitive dysfunction involves changes in reproductive status resulting from chemotherapy. Additionally, the presence of depression may confound the experience of cognitive dysfunction. CONCLUSIONS: A comprehensive description of cognitive dysfunction and improved understanding of the interrelationships among cognitive dysfunction, reproductive hormone levels, and depression in women with breast cancer receiving adjuvant chemotherapy may hasten the development of interventions for the management of cognitive dysfunction. IMPLICATIONS FOR NURSING: Nurses should teach women with breast cancer and their families about the potential for cognitive dysfunction after chemotherapy so the problem can be recognized and interventions can be implemented to help women compensate for the dysfunction.
Authors: Catherine M Bender; Susan M Sereika; Adam M Brufsky; Christopher M Ryan; Victor G Vogel; Priya Rastogi; Susan M Cohen; Frances E Casillo; Sarah L Berga Journal: Menopause Date: 2007 Nov-Dec Impact factor: 2.953
Authors: Michelle C Janelsins; Sadhna Kohli; Supriya G Mohile; Kenneth Usuki; Tim A Ahles; Gary R Morrow Journal: Semin Oncol Date: 2011-06 Impact factor: 4.929
Authors: Pascal Jean-Pierre; Paul C Winters; Tim A Ahles; Michael Antoni; F Daniel Armstrong; Frank Penedo; Steven E Lipshultz; Tracie L Miller; Kevin Fiscella Journal: J Oncol Pract Date: 2011-11-22 Impact factor: 3.840
Authors: Pascal Jean-Pierre; Gary R Morrow; Supriya G Mohile; John Stevenson; Kevin Fiscella; Jennifer J Griggs; Joseph A Roscoe; Jennifer Carroll; Devinder Singh; James Atkins; Ravi Khanna Journal: Treat Strateg Oncol Date: 2011
Authors: Catherine M Bender; Maria L Pacella; Susan M Sereika; Adam M Brufsky; Victor G Vogel; Priya Rastogi; Frances E Casillo; Susan M Richey; Christopher M Ryan Journal: J Support Oncol Date: 2008 May-Jun